Associated Papers
In Silico Binary Classification of Catalytic Function (Unaffected or Impaired) of Flavin-Containing Monooxygenase 3 (FMO3) Variants and in Vitro Validation Using New Variants Found in a Japanese Genome Resource Database.
Shimizu M et al.
Biological & Pharmaceutical Bulletin, 2025
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2024
Novel NARS2 variants in a patient with early-onset status epilepticus: case study and literature review.
Yang N et al.
Bmc Pediatrics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
First Report from Saudi Arabia of Trimethylaminuria Caused by a Premature Stop Codon Mutation in the FMO3 Gene.
Alghanem B et al.
The Application of Clinical Genetics, 2024
Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources.
Makiguchi M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2023
Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.
Yow HY et al.
Asian Biomedicine : Research, Reviews and News, 2023
Bi-allelic mutation in SEC16B alters collagen trafficking and increases ER stress.
El-Gazzar A et al.
Embo Molecular Medicine, 2023
Coding Variants of the FMO3 Gene Are Associated with the Risk of Chronic Kidney Disease: A Case-Control Study.
Shorudi Dadi I et al.
Reports of Biochemistry & Molecular Biology, 2022
A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2021
Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.
Alibrandi S et al.
Molecules (basel, Switzerland), 2021
The pharmacogenetics of treatment with olanzapine.
Zubiaur P et al.
Pharmacogenomics, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Antiretroviral treatment leading to secondary trimethylaminuria: Genetic associations and successful management with riboflavin.
Scimone C et al.
Journal of Clinical Pharmacy and Therapeutics, 2021
Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
Zhu KX et al.
European Journal of Clinical Pharmacology, 2021
N- and S-oxygenation activity of truncated human flavin-containing monooxygenase 3 and its common polymorphic variants.
Bortolussi S et al.
Archives of Biochemistry and Biophysics, 2021
Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X et al.
Pharmacology, 2021
Ligand stabilization and effect on unfolding by polymorphism in human flavin-containing monooxygenase 3.
Catucci G et al.
International Journal of Biological Macromolecules, 2020
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
Phillips IR et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria.
Shimizu M et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2019
Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: 1H NMR spectroscopy and genetic testing.
Bouchemal N et al.
Orphanet Journal of Rare Diseases, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Nicotine-N'-Oxidation by Flavin Monooxygenase Enzymes.
Perez-Paramo YX et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2019
Novel Association between Flavin-Containing Monooxygenase 3 Gene Polymorphism and Antithyroid Drug-Induced Agranulocytosis in the Han Population.
He YY et al.
Annals of Nutrition & Metabolism, 2019
Flavin-Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of Tamoxifen and Clomiphene.
Catucci G et al.
Basic & Clinical Pharmacology & Toxicology, 2018
Minor diplotypes of FMO3 might protect children and adolescents from obesity and insulin resistance.
Morandi A et al.
International Journal of Obesity (2005), 2018
Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain.
Teitelbaum AM et al.
The Pharmacogenomics Journal, 2018
Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.
Woo HI et al.
Oncotarget, 2017
Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.
Xu M et al.
The Journal of Pharmacology and Experimental Therapeutics, 2017
Targeted sequencing identifies genetic polymorphisms of flavin-containing monooxygenase genes contributing to susceptibility of nicotine dependence in European American and African American.
Zhang TX et al.
Brain and Behavior, 2017
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Leong SL et al.
Scientific Reports, 2017
Genetic analysis of impaired trimethylamine metabolism using whole exome sequencing.
Guo Y et al.
Bmc Medical Genetics, 2017
Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients.
Ren L et al.
Pharmacogenomics, 2017
Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.
Woo HI et al.
Drug Design, Development and Therapy, 2017
Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol.
Gonzalez-Covarrubias V et al.
Frontiers in Pharmacology, 2017
Human flavin-containing monooxygenase 3: Structural mapping of gene polymorphisms and insights into molecular basis of drug binding.
Gao C et al.
Gene, 2016
Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3.
Okubo M et al.
Human Psychopharmacology, 2016
Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria.
Shimizu M et al.
Molecular Genetics and Metabolism Reports, 2015
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X et al.
Nature Communications, 2015
Pharmacogenetics of nicotine and associated smoking behaviors.
Tanner JA et al.
Current Topics in Behavioral Neurosciences, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
Uppugunduri CR et al.
The Pharmacogenomics Journal, 2014
Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.
Shimizu M et al.
British Journal of Clinical Pharmacology, 2014
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
Söderberg MM et al.
The Pharmacogenomics Journal, 2013